Subtype
Nasopharyngeal Neoplasm
CI-CAN-00003401Explore in graph →
Non-malignant267 active trials1 approved drugs
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003401Explore in graph →
Clinical trials
825 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) | terminated | Phase 1 / Phase 2 | 42 | GenmabINDUSTRY | 2 | Mar 4, 2026 | clinicaltrials |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | TakedaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies |
| terminated |
| Phase 1 |
| 25 |
| Incyte CorporationINDUSTRY |
| 2 |
| Oct 21, 2025 |
| clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC | terminated | Phase 1 | 26 | Viracta Therapeutics, Inc.INDUSTRY | 8 | Mar 12, 2025 | clinicaltrials |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | terminated | Phase 1 / Phase 2 | 12 | Atara BiotherapeuticsINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB) | terminated | Phase 1 | 160 | Inhibrx Biosciences, IncINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT03682055 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) | terminated | Phase 1 / Phase 2 | 14 | Cullinan Therapeutics Inc.INDUSTRY | 5 | Aug 15, 2023 | clinicaltrials |
| NCT02698111 | Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 20 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | May 8, 2023 | clinicaltrials |
| NCT02569788 | Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 9 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02801487 | Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 6 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02058017 | OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy | terminated | Phase 1 | 9 | National University Hospital, SingaporeOTHER | 1 | Jun 19, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Mar 4, 2026source: clinicaltrials